201 related articles for article (PubMed ID: 31481581)
1. Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
Saadani H; van der Hiel B; Aalbersberg EA; Zavrakidis I; Haanen JBAG; Hoekstra OS; Boellaard R; Stokkel MPM
J Nucl Med; 2019 Nov; 60(11):1545-1552. PubMed ID: 31481581
[TBL] [Abstract][Full Text] [Related]
2. Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in
Zhang Y; Cheng C; Liu Z; Wang L; Pan G; Sun G; Chang Y; Zuo C; Yang X
Med Phys; 2019 Oct; 46(10):4520-4530. PubMed ID: 31348535
[TBL] [Abstract][Full Text] [Related]
3. Potential feature exploration and model development based on 18F-FDG PET/CT images for differentiating benign and malignant lung lesions.
Zhang R; Zhu L; Cai Z; Jiang W; Li J; Yang C; Yu C; Jiang B; Wang W; Xu W; Chai X; Zhang X; Tang Y
Eur J Radiol; 2019 Dec; 121():108735. PubMed ID: 31733432
[TBL] [Abstract][Full Text] [Related]
4. The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III-IV BRAF -Mutated Melanoma Patients Treated With Targeted Therapy-What Can Be Learned From Progression?
van der Hiel B; Aalbersberg EA; van den Eertwegh AJM; de Wit-van der Veen LJ; Stokkel MPM; Lopez-Yurda M; Boellaard R; Kapiteijn EW; Hospers GAP; Aarts MJB; de Vos FYFL; Boers-Sonderen MJ; van der Veldt AAM; de Groot JWB; Haanen JBAG
Clin Nucl Med; 2024 Feb; 49(2):138-145. PubMed ID: 38113329
[TBL] [Abstract][Full Text] [Related]
5. CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases.
Olthof SC; Krumm P; Weichold O; Eigentler T; Bösmüller H; la Fougère C; Pfannenberg C; Martus P; Klumpp B
Eur J Radiol; 2020 Oct; 131():109242. PubMed ID: 32942199
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.
van der Hiel B; Haanen JBAG; Stokkel MPM; Peeper DS; Jimenez CR; Beijnen JH; van de Wiel BA; Boellaard R; van den Eertwegh AJM;
BMC Cancer; 2017 Sep; 17(1):649. PubMed ID: 28915798
[TBL] [Abstract][Full Text] [Related]
7. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract][Full Text] [Related]
8. Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
Schmitt RJ; Kreidler SM; Glueck DH; Amaria RN; Gonzalez R; Lewis K; Bagrosky BM; Kwak JJ; Koo PJ
Nucl Med Commun; 2016 Feb; 37(2):122-8. PubMed ID: 26440571
[TBL] [Abstract][Full Text] [Related]
9.
Young JR; Johnson GB; Murphy RC; Go RS; Broski SM
J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410
[TBL] [Abstract][Full Text] [Related]
10. Performance of
Zhang M; Bao Y; Rui W; Shangguan C; Liu J; Xu J; Lin X; Zhang M; Huang X; Zhou Y; Qu Q; Meng H; Qian D; Li B
Front Oncol; 2020; 10():568857. PubMed ID: 33134170
[TBL] [Abstract][Full Text] [Related]
11. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
12. Radiomics analysis of pre-treatment [
van Helden EJ; Vacher YJL; van Wieringen WN; van Velden FHP; Verheul HMW; Hoekstra OS; Boellaard R; Menke-van der Houven van Oordt CW
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2307-2317. PubMed ID: 30094460
[TBL] [Abstract][Full Text] [Related]
13. Use of radiomics based on
Zhou Y; Ma XL; Zhang T; Wang J; Zhang T; Tian R
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2904-2913. PubMed ID: 33547553
[TBL] [Abstract][Full Text] [Related]
14. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between
Chang JW; Park KW; Heo JH; Jung SN; Liu L; Kim SM; Kwon IS; Koo BS
World J Surg; 2018 Jan; 42(1):114-122. PubMed ID: 28808756
[TBL] [Abstract][Full Text] [Related]
16. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
17. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
18. Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features.
Eertink JJ; Zwezerijnen GJC; Cysouw MCF; Wiegers SE; Pfaehler EAG; Lugtenburg PJ; van der Holt B; Hoekstra OS; de Vet HCW; Zijlstra JM; Boellaard R
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4642-4651. PubMed ID: 35925442
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Volumetric Parameters Measured by Pretreatment 18F FDG PET/CT in Patients With Cutaneous Malignant Melanoma.
Son SH; Kang SM; Jeong SY; Lee SW; Lee SJ; Lee J; Ahn BC
Clin Nucl Med; 2016 Jun; 41(6):e266-73. PubMed ID: 27055144
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients: Can (Early) Metabolic Imaging Predict Histopathologic Response or Recurrence?
van der Hiel B; Blankenstein SA; Aalbersberg EA; Wondergem M; Stokkel MPM; van de Wiel BA; Klop WMC; van Akkooi ACJ; Haanen JB
Clin Nucl Med; 2022 Jul; 47(7):583-589. PubMed ID: 35452004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
